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ess: dr_chaoliu@yahoo.Summary Pulmonary arterial hypertension (PAH) is a devastating disease that
leads to right heart failure and premature death. Historically, we are restricted by
limited options for drug treatment. Over the past decade, with advances in our
understanding of pathophysiological and molecular mechanisms, many new
therapeutic strategies (synthetic prostacyclin and prostacyclin analogues, endothe-
lin receptor antagonists and sildenafil) have been developed for the treatment of
PAH, and the clinical efficacy has been tested in many randomized-controlled trials
(RCTs). In this overview, we review the evidence for the use of historical and new
treatments that arises from the Cochrane Collaboration of Systematic Reviews and
from recent RCTs.
& 2006 Elsevier Ltd. All rights reserved.Background
Pulmonary arterial hyptertension (PAH) is a disease
of the small pulmonary arteries that is character-
ized by vascular proliferation and remodelling,1
which lead to progressive increase in pulmonary
vascular resistance and, ultimately, right ventricu-
lar failure and death.
Pulmonary hypertension was previously classified
as primary (idiopathic) or secondary.1 It is now
clear, however, that both groups share the same
histopathological features and have similar re-Elsevier Ltd. All rights reserv
ve been cited in this evidence-
iu C, et al. Endothelin recepto
monary hypertension, Issue 4,
com.cn (C. Liu).sponse to treatment, even though conditions within
the category of secondary pulmonary hypertension
are highly variable. For this reason, the World
Health Organization (WHO) has reclassified pul-
monary hypertension into five groups based on their
mechanisms,2 rather than associated conditions.
These five subcategories are as follows: (1) idio-
pathic PAH; (2) familial PAH; (3) PAH associated
with collagen vascular disease, congenital sys-
temic-to-pulmonary shunts, portal hypertension,
HIV infection, drugs and toxins or other (thyroid
disorders, glycogen storage disease, Gauchered.
based review. Paramothayan NS, et al. Prostacyclin for pulmonary
r antagonists for pulmonary arterial hypertension. Issue 1, 2005;
2004.
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C. Liu et al.766disease, hereditary haemorrhagic telangiectasia,
haemoglobinopathies, myeloproliferative disor-
ders, and splenectomy); (4) PAH associated with
significant venous or capillary involvement, which
includes pulmonary veno-occlusive disease and
pulmonary capillary haemangiomatosis; and (5)
persistent pulmonary hypertension of the newborn.
In this overview, we will focus principally on
category 1 of the WHO classification, which for
simplicity we have labelled pulmonary arterial
hypertension (PAH).Pathophysiological features
The pathogenesis of PAH involves multiple mechan-
isms. However, three common factors are thought
to cause the increased pulmonary vascular resis-
tance that characterizes this devastating disease:
vasoconstriction, pulmonary vascular proliferation
and remodelling, and thrombosis in situ.3 Advances
in our knowledge of the molecular mechanisms
involved in PAH suggest that endothelial dysfunc-
tion with chronic impaired production of vasoactive
mediators plays a key role.4–6 Reduced production
of vasoactive mediators, such as nitric oxide and
prostacyclin, along with overexpression of vaso-
constrictors, such as endothelin-1 (ET-1), affect
vascular tone and also promote vascular remodel-
ling. Therefore, these substances represent logical
pharmacological targets.Natural history and survival
A patient is diagnosed with PAH when the mean
pulmonary artery pressure becomes greater than
25mmHg at rest or 30mmHg with exercise.7 The
most common symptoms include exertional breath-
lessness, chest pain and syncope. However, these
symptoms are not specific to PAH, and are often
associated with other cardiorespiratory diseases.
The delay between the first onset of symptoms and
the diagnosis of PAH may be up to 3 years, and yet
the mean survival time for untreated patients with
severe pulmonary hypertension has been reported
to be 2 years.8End points in clinical trials
The advent of new drugs in recent years has
promoted the challenge of how to best assess and
monitor the efficacy of new treatment. It is
unethical to use long-term survival as a clinicalend point because of rapid disease progression and
poor prognosis. Thus, alternative measurements
are required. The normalization of measures of
cardiovascular haemodynamics would be an ideal
end point, if it were possible. However, the
correlation between resting haemodynamic im-
provement and clinical response is poor in clinical
trials.
The Six-Minute Walk Test (6MW), in which the
patient walks as far as possible in 6min, is a
submaximal exercise test that can be carried out by
patients who cannot tolerate a maximal exercise
test.9 It is simple, safe, reliable and a highly
reproducible tool for the assessment of exercise
capacity in patients with PAH. Furthermore, it is an
independent predictor of mortality.9 Thus, the 6MW
has been widely used as a primary end point in
clinical trials.
Although the identification of functional class is
subject to the bias of investigators, the New York
Heart Association (NYHA) or the WHO functional
class has been an important end point in clinical
trials of PAH, and improvement of NYHA/WHO
functional class is associated with a prolonged life
expectancy.8,10
In the present overview, we will review the
evidence for the use of treatments for PAH from
Cochrane systematic reviews. We will also discuss
treatments not covered by Cochrane reviews (e.g.
calcium-channel blockers [CCBs], diuretics and
digoxin).Basic treatments
Diuretics, digoxin, oxygen and anticoagulation
Dramatic symptom improvement and clinical ben-
efits in patients with right heart failure can be
achieved by instituting diuretic therapy. The
efficacy of diuretics in treating symptoms has
resulted in an unwillingness among physicians
treating these patients to carry out a placebo-
controlled trial of diuretics in this condition.
Because of lack of evidence from randomized-
controlled trials (RCTs), the drug of choice has to be
dependent on the experience of physicians.
Short-term use of intravenous digoxin in idio-
pathic pulmonary arterial hypertension (IPAH)
produces a modest increase in cardiac output and
a significant reduction in circulating norepinephr-
ine11; however, no data are available from RCTs to
confirm its efficacy in long-term treatment. The
value of digoxin is when left ventricular failure is
also present. It may also be most useful in treating
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fibrillation.
Theoretically, patients with PAH develop hypox-
aemia because of severe impairment of cardiac
output or right-to-left shunting. Low-flow supple-
mental oxygen may be indicated to maintain
arterial oxygen saturation at a level above 90%.
However, in an RCT of Eisenmenger syndrome,
nocturnal oxygen therapy had no effect on haema-
tological variables, quality of life or survival.12
The evidence for anticoagulant therapy in
patients with PAH is from two single-centre, non-
randomized trials.13,14 The survival of patients
receiving anticoagulation therapy, selected on the
basis of clinical judgement, was improved com-
pared with a concurrent population not receiving
anticoagulation therapy. Three-year survival im-
proved from 21% to 49% in the series from Fuster
et al.13 and from 31% to 47% in the series by Rich
et al.14 On the basis of these trials, anticoagulation
therapy has been widely used in clinical practice,
and has been included in the most recent clinical
trials as a background therapy.Treatments covered in Cochrane
systematic reviews
Synthetic prostacyclin and prostacyclin
analogues
Prostacyclin is a metabolite of arachidonic acid,
and is endogenously produced by vascular endothe-
lium. It is a potent vasodilator in pulmonary and
systemic circulations, and has antiplatelet aggre-
gatory activity. A relative deficiency of prostacyclin
may contribute to the pathogenesis of PAH.6,15
Intravenous prostacyclin (epoprostenol)
A recently updated Cochrane systematic review16
on this topic pooled data from three RCTs,17–19 and
showed a significant treatment effect in favour of
intravenous prostacyclin, with a standardized mean
difference of 0.69 (95% confidence intervals [CI]
0.40–0.97) (Fig. 1) after 8–12 weeks of treatment.
The effect size was similar in all three trials. A
pooled estimate shows the difference in the 6MW
distance between two treatments is similar in all
three trials at around 90m.
In an analysis of pooled data of two studies in
idiopathic PAH, and one study in scleroderma,
improvement in NYHA/WHO function class drama-
tically improved in the group treated with prosta-
cyclin, with an odds ratio (OR) of 37.99 (95% CI8.43–171.22) (Fig. 2). The pooled data also showed
that continuous intravenous administration of
prostacyclin could reduce mean pulmonary artery
pressure by 6.30mmHg (95% CI8.68 to 3.92).16
Patients with scleroderma treated with prostacy-
clin were more likely to improve NYHA functional
status by at least one class compared with placebo
(OR 67.23, 95% CI 3.95–1145.30) (Fig. 2).
Intravenous prostacyclin therapy requires con-
tinuous intravenous infusion because of its short
half-life (o6min) and inactivation in low pH. It is
unstable at room temperature, and is generally
kept cold before infusion. Despite its role in
improving clinical function in some patients,
intravenous prostacyclin infusion is far from the
ideal treatment for PAH, as it is complicated,
uncomfortable for patients and costly. Common
side-effects include jaw pain, headache, diar-
rhoea, flushing, leg pain and nausea, although they
are generally mild and dose-related. More serious
complications are usually related to the delivery
system. The incidence of catheter-related sepsis
ranges from 0.1–0.6 case per patient-year. Pump
failure or dislocation of the central venous cathe-
ter, leading to an interruption in drug infusion, may
have life-threatening effects on haemodynamics.Subcutaneous treprostinil
To overcome the drawbacks of epoprostenol,
treprostinil, a stable prostacyclin analogue with a
half-life of 3 h, has been developed for subcuta-
neous delivery.
The recently updated Cochrane systematic re-
view16 includes two RCTs,20,21 but no pooled data
are available. The study by Simonneau et al.20
involved 470 patients who had primary pulmonary
hypertension, PAH secondary to a congenital left-
to-right shunt or connective-tissue disease. The
data showed a statistically significant improvement
in median exercise capacity from baseline in the
treprostinil group compared with the placebo group
after 12 weeks of treatment (10m [24 to +47] in
the treprostinil group compared with 0m [44 to
+32] in the placebo-treated group, P ¼ 0:006). The
effect on exercise test seemed to be dose related.
McLaughlin et al.21 reported no significant differ-
ence in mean change of 6MW from baseline
between treprostinil and placebo, but the sample
size was just only 26. Common side-effects of
treprostinil were similar to epoprostenol, which
included headache, diarrhoea, nausea, rash, jaw
pain and infusion site pain. Local pain at the
infusion site was a side-effect that occurred in 85%
of patients, which precluded an increased dose in a
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Figure 2 Systematic review evidence for the improvement in NYHA/WHO class in patients with pulmonary arterial
hypertension treated with intravenous prostacyclin.
Figure 1 Systematic review evidence for increase in the Six-Minute Walk Test distance in patients with pulmonary
arterial hypertension treated with intravenous prostacyclin.
C. Liu et al.768substantial proportion of patients and led to
discontinuation of treatment in 8% of patients.
As there is bio-equivalence with the subcuta-
neous route, treprostinil can also be used intrave-nously.22 Non-randomized trial data show that this
drug does not have the same dose-limiting pro-
blems as with the subcutaneous route, but con-
fers several major advantages over intravenous
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half-life and improved convenience to patients).
Inhaled iloprost
Inhaled therapy for pulmonary hypertension may
provide selectivity of the haemodynamic effects to
the lung vasculature, thus avoiding systemic side-
effects. Iloprost is a chemically stable prostacyclin
analogue (half-life is 20–25min) that can be
delivered by inhaler to patients with PAH. It has
the same biologic profile as the natural substance
that produces prostaglandin receptor binding and
cellular effects.23 Its effects and its side-effects
are similar to those seen during epoprostenol
infusion.24
To date, the Cochrane systematic review16 has
only included one 12-week randomized, multi-
centre, placebo-controlled trial involving 203 pa-
tients (all in NYHA functional class III or IV), with
primary pulmonary hypertension, PAH associated
with connective-tissue diseases or inoperable
chronic thromboembolic pulmonary hyperten-
sion.25 After 12 weeks of treatment, patients
receiving inhaled iloprost significantly improved
their 6MW capacity (change from baseline) by
36.40m (95% CI 12.04–60.76; P ¼ 0:004) compared
with the placebo group. They were also more likely
to improve in NYHA functional class (OR 2.13, 95%
CI 1.02–4.48). These short-term results are en-
couraging; however, long-term efficacy of inhaled
iloprost remains to be confirmed.
Oral beraprost
Beraprost, the first orally active prostacyclin
analogue, is rapidly absorbed during fasting. ItsFigure 3 Systematic review evidence for improvement in
hypertension treated with oral beraprost.peak concentration is reached after 30min, and the
elimination half-life is 35–40min after oral admin-
istration.26 The Cochrane systematic review16
included two RCTs27,28 (with duration of 12 weeks
or 12 months, respectively). No pooled data on
6MW distance were available. However, Galie
et al.28 reported a significant difference in favour
of beraprost (25.1m, 95% CI 1.8–48.3; P ¼ 0:036),
with a greater improvement in participants with
primary pulmonary hypertension (24.4m in the
beraprost group vs. 22.8m in the placebo group).
In participants with pulmonary hypertension due to
other causes, the mean change was 5.7m on
beraprost and 0.6m on placebo (all values at 12
weeks). The data from Barst et al.27 showed no
significant difference in median change from base-
line in 6MW distance between the two treatments
at 12 months (23m, P ¼ 0:18).
The pooled data do not show a significant
improvement of NYHA/WHO function class in the
group treated with oral beraprost compared with
the placebo group (OR 1.43, 95% CI 0.71–2.88;
P ¼ 0:3814) (Fig. 3). Trials showed beneficial
effects in clinical symptoms, exercise capacity
and haemodynamic measurements at 12 weeks;
however, the effects attenuated with time in the
study by Barst et al.,27 and no significant changes
occurred in haemodynamics or survival at 12
months. This emphasizes the limitations of 12-
week clinical studies involving patients with PAH.Endothelin receptor antagonists
Endothelin receptor antagonists (ERAs) have re-
cently been proposed as a new alternative to
traditional treatments. ERAs are potent vasodilatorsNYHA/WHO class in patients with pulmonary arterial
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dilate and remodel the pulmonary arterial system.
Two separate receptors for endothelin (ET) have
been identified. ET-A receptors are most commonly
found on vascular smooth-muscle cells, and induce
vasoconstriction by increasing intracellular calcium.
ET-B receptors are located on endothelial cells
and stimulate the release of vasodilating agents
such as nitric oxide and prostacyclin. However,
ET-B receptors also appear on vascular smooth
muscle cells, where they stimulate vasoconstric-
tion. Theoretically, either selective block of
ET-A receptors alone or non-selective block of
ET-A and ET-B receptors together can dilate the
local vessels.
A recently published Cochrane systematic re-
view29 on this topic included three RCTs.30–32 The
findings suggest that either a non-selective ERA
(bosentan) or a selective ET-A receptor antagonist
(sitaxsentan) could significantly improve 6MW dis-
tance and NYHA/WHO functional status. Pooled
data using generic inverse variance method
(authors used this method because there was no
specific mean7standard deviation available) on
bosentan showed that exercise capacity improve-
ment was significantly greater in participants
treated with this ERA: 46.24m (95% CI
23.96–68.53) (Fig. 4). By week 12, both the lower
dose of sitaxsentan (100mg) and the higher dose
(300mg) had significantly improved exercise capa-
city (35m in the lower dose group, Po0:01; 33m in
higher dose group, Po0:01) compared with place-
bo. As for NYHA/WHO functional class, the pooled
data showed that, overall, ERAs significantly
improved functional class in patients with PAH
compared with placebo. The relative risk (RR) wasFigure 4 Systematic review evidence for increasing the Six
arterial hypertension treated with endothelin receptor antago
Library, as it shows the number of participants in the two gr1.65 (95% CI 1.17–2.32) (Fig. 5). The RR for the non-
selective ERA was 1.52 (95% CI 1.02–2.26), whereas
the RR for the selective ERA was 1.98 (95% CI
1.02–3.84).
A major concern about ERAs is hepatic toxicity.
However, the data pooled in the Cochrane review
showed that the events were rare, probably dose-
dependant, and that a low dose of ERA is safer than
a high dose.Sildenafil
Phosphodiesterase (PDE)-type 5 inhibitors, such as
sildenafil, selectively dilate pulmonary artery
through enhancing nitric oxide-dependent, cyclic
guanosine monophosphate mediated pulmonary
vasodilatation by inhibition of the breakdown of
cyclic guanosine monophosphate. In animal experi-
ments, sildenafil, used for treating pulmonary
hypertension, was proved to be a potent and
pulmonary-selective vasodilator.33
A Cochrane review34 on the subject of sildenafil
for pulmonary hypertension included four
RCTs.35–38 Two of these trials tested the acute
haemodynamic changes after giving sildenafil.37,38
The other two35,36 were randomized, double-blind,
crossover studies, with durations of 2 and 6 weeks,
respectively. Data were pooled on 6MW or improve-
ment in NYHA function; however, both trials
reported a significant improvement in exercise
capacity. Only Bharani et al.36 reported the out-
come of improvement in NYHA function, but no
significant difference was found between two
groups. In light of the limitations created by small-Minute Walk Test distance in patients with pulmonary
nists. This graph differs from the original in the Cochrane
oups.
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Figure 5 Systematic review evidence for the improvement in NYHA/WHO class in patients with pulmonary arterial
hypertension treated with endothelin receptor antagonists.
Treatments for pulmonary arterial hyptertension 771sample size (nine in Bharani et al.36 and 22 in Sastry
et al.35), and relatively short study duration, the
findings should be interpreted with caution.
A double-blind, placebo-controlled study (SUPER
study) was recently published in the New England
Journal of Medicine.39 Two hundred and seventy-
eight patients with symptomatic pulmonary arterial
hypertension (either idiopathic, associated with
connective tissue disease or with repaired con-
genital systemic-to-pulmonary shunts) were rando-
mized to placebo or sildenafil (20, 40 or 80mg)
orally three times daily for 12 weeks. At week 12,
the 6MW distance increased from baseline in all
sildenafil groups. The mean placebo-corrected
treatment effects were 45m (99% CI 21–70;
Po0:001), 46m (99% CI 20–72), and 50m (99% CI
23–77) for 20, 40 and 80mg of sildenafil, respec-
tively (Po0:001 for all comparisons). As for the
WHO functional class, the proportions of patients
with an improvement of at least one functional
class was significantly higher in sildenafil groups
compared with the placebo group. The placebo-
corrected treatment effects were 21% in the 20mg
sildenafil group (95% CI 9–33%; P ¼ 0:003), 29% in
the 40mg sildenafil group (95% CI 16–42%;
Po0:001), and 35% in the 80mg sildenafil group
(95% CI 22–48%; Po0:001), respectively. Among the
222 patients completing 1 year of treatment with
sildenafil monotherapy, the improvement from
baseline at 1 year in the 6MW distance was 51m.Calcium channel blockers
No RCTs or Cochrane systematic reviews have been
published on Calcium channel blockers (CCBs) in
patients with PAH, yet favourable clinical and
prognostic effects of high doses of CCB drugs in
vasoreactive patients with IPAH have been shown in
uncontrolled clinical studies.14,40 The definition of
‘‘a positive acute vasoreactive response’’ refers to
reduction of the mean pulmonary artery pressure
by more than 10mmHg, to a value lower than
40mmHg, with a normal or high cardiac out-
put during acute vasodilator challenge (intravenous
prostacyclin, adenosine or inhaled nitric oxide).41
Generally, only about 10–15% of patients with
IPAH will meet these criteria. A group of highly
selected patients with an acute vasoactive re-
sponse may benefit from a CCB.40,41 Em-
piric treatment with CCBs in patients without
acute vasoreactivity test is discouraged, because
of possible adverse effects or an inappro-
priate delay in patients receiving more effective
treatments.Discussion
In this paper, we have examined the evidence for
the use of various new drugs in PAH from Cochrane
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RCTs have tested the efficacy of drugs used for
treating pulmonary hypertension. However, the
predominant population in most of the trials was
sporadic IPAH and PAH associated with scleroderma
or appetite supressant use. Most patients in the
trials were categorized as NYHA/WHO functional
class III or IV. Therefore, extrapolation of these
results to the other PAH subgroups should be done
with caution.
Study duration in most of the RCTs ranged from 8
to 12 weeks. The long-term effects of new
treatments are still unknown. Survival, quality of
life, side-effects and costs of treatments still need
to be evaluated in long-term observational studies.
As few data are available from head-to-head
trials with comparisons of approved drugs, the
choice of drug is dependent on a variety of factors,
including the availability of drugs, physicians’
clinical experience, comorbidities and patients’
preferences.
Combination therapy is an attractive option to
treat the multiple pathophysiological mechanisms
in PAH.41,42 Combination therapy might be pursued
by the simultaneous initiation of two (or more)
treatments or by the addition of a second (or
third) treatment to a previous treatment that
is considered insufficient. The choice of best
strategy is currently unknown, as data are limited.
One pilot study involving bosentan and intravenous
prostacyclin with a small sample explored its
efficacy and safety, which favoured combination
therapy.43 Non-randomized data from Hoeper
et al.44 suggest that a therapeutic approach
using combinations of bosentan, sildenafil and
inhaled iloprost, according to a goal-oriented
treatment strategy, provides acceptable long-
term results in patients with severe pulmonary
arterial hypertension, and reduces the need for
intravenous prostaglandin treatment and lung
transplantation.Conclusion
Historically, we have been restricted by the limited
choice of therapeutic options. Over the past
decade, with advances in our understanding of
pathophysiological and molecular mechanisms of
PAH, new drugs and regimens have been developed
and tested in RCTs. These show promising effects
on clinical outcomes, giving renewed hope for both
patients and physicians involved in treating these
disorders. Evidence-based guidelines and algo-
rithms are emerging to guide practice.41,42Practice points
 In light of the complexity of this disease and
the treatments outlined, patients with PAH
should be referred to specialist centres with
experience in managing this disease
 ERAs, sildenafil or a prostacyclin analogue
are first-line therapies for patients with PAH
with NYHA/WHO functional class III
 Intravenous prostacyclin is the first-line
therapy for patients with PAH with NYHA/
WHO functional class IV
 A group of highly selected patients with a
positive acute vasoreactive response may
benefit from a CCBResearch directions
 The role of ERAs, synthetic prostacyclin and
prostacyclin analogues, and PDE inhibitors
in early PAH (i.e. WHO class II and I)
 The efficacy of combined use of drugs with
ERAs, synthetic prostacyclin and prostacy-
clin analogues, and PDE inhibitors
 Long-term effects of ERAs, synthetic pros-
tacyclin analogues and PDE inhibitors in
survival, quality of life and side-effectsAcknowledgements
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